The Austrian biotech-company, Haplogen, specializing in the discovery of medicaments against infections, has sold its subsidiary Haplogen Genomics. With this acquisition, Horizon Discovery secured Haplogen`s Gene-Editing-Plattform which can be used by universities and research centres for cost-saving research procedures. The price of EUR 7,7 mio was paid in cash and shares. Additionally, they agreed on a success-depending component with a value of EUR 5 Mio. The law firm Wolf Theiss advised the buy-side on the due diligence of the complete transaction. Under the lead of corporate partner Dieter Spranz, consultant Daniela Wieser and associate Clara Gordon worked on the acquisition. Partners Georg Kresbach and Matthias Unterrieder handled all the issues regarding intellectual property and employment law. The UK based law firm Covington & Burling LLP advised Horizon Discovery regarding English law.
WOLF THEISS REPRESENTS HORIZON DISCOVERY ON ITS ACQUISITION OF HAPLOGEN GENOMICS